Disruption of KATP channel expression in skeletal muscle by targeted oligonucleotide delivery promotes activity-linked thermogenesis

Despite the medical, social and economic impact of obesity, only a few therapeutic options, focused largely on reducing caloric intake, are currently available and these have limited success rates.A major impediment is that any challenge by caloric restriction is counterbalanced by activation of systems that conserve energy to prevent body weight loss.Therefore, targeting energy-conserving mechanisms to promote energy expenditure is an attractive strategy for obesity treatment.Here, in order to suppress muscle energy efficiency, we target sarcolemmal ATP-sensitive potassium (KATP) channels which have previously been shown to be important in maintaining muscle energy economy. Specifically, we employ intramuscular injections of cell-penetrating vivo-morpholinos to prevent translation of the channel pore-forming subunit. This intervention results in significant reduction of KATP channel expression and function in treated areas, without affecting the channel expression in non-targeted tissues. Furthermore, suppression of KATP channel function in a group of hind limb muscles causes a substantial increase in activity-related energy consumption, with little effect on exercise tolerance. These findings establish a proof-of-principle that selective skeletal muscle targeting of sarcolemmal KATP channel function is possible and that this intervention can alter overall bodily energetics without a disabling impact on muscle mechanical function. Corrigendum, Molecular Therapy (2015); 23 11, 1794. doi:10.1038/mt.2015.186 In the Materials and Methods section under “Vivo-morpholino,” the amount of oligonucleotides was incorrectly described as 2 nmol/l in 50 µl normal saline (about 1 ng). The correct amount is 2 nmol in 50 µl normal saline (approximately 20 µg), split between 2-3 injections per muscle. The authors regret the error.